Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02213107
Title Enzalutamide & Dutasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Rochester

prostate adenocarcinoma


Dutasteride + Enzalutamide

Age Groups: senior
Covered Countries USA

No variant requirements are available.